Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821647 | 0.83 | NAMPT (0.38) | ACHENAMPTKDM5BPRMT5WDR77 | |
| SCHEMBL11968682 | 0.79 | ACHE (0.47) | ACHEPDK2NAMPTKDM5BPRMT5 | |
| SCHEMBL18858532 | 0.79 | ACHE (0.47) | ACHEPDK2NAMPTKDM5BPRMT5 | |
| SCHEMBL12092593 | 0.79 | MAPT (0.37) | ACHEESR1 | |
| SCHEMBL15978917 | 0.79 | PDK2 (0.35) | PDK2ESR1 | |
| SCHEMBL2410092 | 0.78 | ACHE (0.46) | ACHEPDK2NAMPTKDM5BPRMT5 | |
| SCHEMBL12776229 | 0.76 | L3MBTL1 (0.50) | NAMPTKDM5BPRMT5WDR77MAPK1 | |
| SCHEMBL21502004 | 0.76 | ACHE (0.45) | ACHEPDK2NAMPTKDM5BPRMT5 | |
| SCHEMBL23139159 | 0.75 | ACHE (0.44) | ACHEPDK2NAMPTKDM5BPRMT5 | |
| SCHEMBL10203202 | 0.74 | ACHE (0.49) | ACHEPDK2NAMPTKDM5BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | ACHE 4862/4885PDK2 98/4885NAMPT 596/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | ACHE 4862/4885PDK2 98/4885NAMPT 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.